Cohort and registry studies demonstrate that lifetime UTUC risks in MSH2 carriers can exceed those for bladder cancer, with a high rate of metachronous contralateral upper-tract tumors and frequent multifocal disease [51,59]. Here, MSH2 is linked to renal pelvis/ureter urothelial carcinoma.